Micromet announces presentation of updated results from MT103 Phase 2 trial in MRD positive ALL patients

Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 2 trial of the Company's lead product candidate blinatumomab (MT103) in adult patients with minimal residual disease (MRD) positive acute lymphoblastic leukemia (ALL). An analysis of long-term efficacy data demonstrated that blinatumomab produced prolonged remissions in patients with ALL. As of November 2010, the hematologic disease free survival (DFS) was 60%, with a follow-up of up to 27.5 months. Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

“The experience to date supports our belief in blinatumomab's potential to change the long-term outlook for patients with ALL. We look forward to further expanding our ALL development program in 2011.”

The data were reported in an oral presentation (abstract # 174) today at the 52nd American Society of Hematology (ASH) Annual Meeting in Orlando, FL.

"Blinatumomab continues to produce durable remissions in patients with ALL, with no relapses seen since the ASH 2009 Annual Meeting," said Christian Itin, Ph.D, President and CEO. "The experience to date supports our belief in blinatumomab's potential to change the long-term outlook for patients with ALL. We look forward to further expanding our ALL development program in 2011."